Aurore Perrot

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 202 publications

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: June 15, 2026

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Journal: The New England journal of medicine

Published: May 29, 2026

Five trials reshaping multiple myeloma.

Five trials reshaping multiple myeloma.

Journal: Med (New York, N.Y.)

Published: May 01, 2026

Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study.

Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study.

Journal: Leukemia

Published: April 27, 2026

Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma.

Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma.

Journal: Future oncology (London, England)

Published: April 27, 2026

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy.

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 20, 2026

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.

Journal: Blood advances

Published: March 27, 2026

Maintenance intensification after autologous HSCT: refining selection.

Maintenance intensification after autologous HSCT: refining selection.

Journal: The Lancet. Haematology

Published: February 21, 2026

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

Journal: Blood

Published: February 19, 2026

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Journal: Leukemia

Published: February 18, 2026

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Journal: Journal of medical economics

Published: February 17, 2026

Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.

Atypical mast cells and multiple myeloma: An ambiguous alliance with diagnostic implications.

Journal: British journal of haematology

Published: February 16, 2026

Showing 1-12 of 202

Last Updated: 09/26/2026